⬇️ Link in my bio
Use promo code "WHYNOT" for 💌
$80 free credit on GreenRush.com 💸
[Over 250+ Deliveries in CA]
In June, for the first time, The Food and Drug Administration approved a plant-derived medicine from marijuana. The prescription drug, known as Epidiolex, contains a proprietary formulation of cannabis' organic compounds - primarily cannabidiol (CBD) -for the treatment of severe seizure disorders.
The British pharmaceutical company - the manufacturer of the drug - a has long been licensed by the U.K. government to privately grow strains of cannabis for the purpose of drug development.
But no such avenue currently exists for marijuana-based drug development in the United States. That is because, unlike in Great Britain (and in various other countries, like Canada and Israel), neither privately grown cannabis nor products derived from privately grown cannabis may be administered to subjects in the course of an FDA-approved clinical trial. This also includes those manufactured by state-licensed and compliant manufacturers
Instead, investigators must obtain whole-plant cannabis from a single source: The University of Mississippi, which since 1968 has held the only federal licensed to cultivate cannabis for research purposes.
But, even today, the variety of products offered via the U-Miss supply chain is exceedingly limited and, far too often, of poor quality. According to its current menu, only six distinct strains of cannabis are available to researchers.
These strains range from between zero percent THC to 6.7 percent THC, far below the average potency of available products in legal states or on the black market. Furthermore, none of the available products contain even close to one percent CBD - a therapeutic compound of growing interest to scientists.
Continued In Comments
#losangeles #la #california #cannabiscommunity #cannabis
marijuana youseshwework real
life weshouldsmoke beardbros_pharms yourfavoritegrowersfavoritegrower EndMarijuanaProhibition